Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma by Kai-chao Feng et al.
CASE REPORT Open Access
Cocktail treatment with EGFR-specific and
CD133-specific chimeric antigen receptor-
modified T cells in a patient with advanced
cholangiocarcinoma
Kai-chao Feng1, Ye-lei Guo2, Yang Liu3, Han-ren Dai2, Yao Wang2, Hai-yan Lv2, Jian-hua Huang2,
Qing-ming Yang1 and Wei-dong Han1,2*
Abstract
Background: Cholangiocarcinoma (CCA) is one of the most fatal malignant tumors with increasing incidence, mortality,
and insensitivity to traditional chemo-radiotherapy and targeted therapy. Chimeric antigen receptor-modified T cell
(CART) immunotherapy represents a novel strategy for the management of many malignancies. However, the potential
of CART therapy in treating advanced unresectable/metastatic CCA is uncharted so far.
Case presentation: In this case, a 52-year-old female who was diagnosed as advanced unresectable/metastatic CCA
and resistant to the following chemotherapy and radiotherapy was treated with CART cocktail immunotherapy, which
was composed of successive infusions of CART cells targeting epidermal growth factor receptor (EGFR) and CD133,
respectively. The patient finally achieved an 8.5-month partial response (PR) from the CART-EGFR therapy and a 4.5-
month-lasting PR from the CART133 treatment. The CART-EGFR cells induced acute infusion-related toxicities such as
mild chills, fever, fatigue, vomiting and muscle soreness, and a 9-day duration of delayed lower fever, accompanied by
escalation of IL-6 and C reactive protein (CRP), acute increase of glutamic-pyruvic transaminase and glutamic-oxalacetic
transaminase, and grade 2 lichen striatus-like skin pathological changes. The CART133 cells induced an intermittent
upper abdominal dull pain, chills, fever, and rapidly deteriorative grade 3 systemic subcutaneous hemorrhages and
congestive rashes together with serum cytokine release, which needed emergent medical intervention including
intravenous methylprednisolone.
Conclusions: This case suggests that CART cocktail immunotherapy may be feasible for the treatment of CCA as well as
other solid malignancies; however, the toxicities, especially the epidermal/endothelial damages, require a further
investigation.
Trial registration: ClinicalTrials.gov NCT01869166 and NCT02541370.
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Background
Cholangiocarcinoma (CCA) represents a diverse group of
highly invasive epithelial cancers arising from different lo-
cations within the biliary tree showing markers of cholan-
giocyte differentiation [1]. Despite CCA is relatively rare,
accounting for approximately 3% of all gastrointestinal
tumors, the incidence seems to be increasing, especially in
the Asian population [2]. Complete surgical resection is
the only preferred option for all patients diagnosed with
CCA. Unfortunately, most of the patients are not qualified
for complete resection because of the delayed diagnosis
and advanced stage of the disease. For patients with unre-
sectable or metastatic CCA, combination chemotherapy
involving gemcitabine and cisplatin is the current recom-
mended standard care of management, and various
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targeted agents have also been tested in several phase I
and II clinical trials [3, 4]. However, the highly desmoplas-
tic nature of CCA as well as its extensive support by a rich
tumor microenvironment and profound genetic hetero-
geneity contribute to its resistance to chemotherapy and
targeted therapy, resulting in poor overall response rate
(ORR) and overall survival (OS) [5].
Successful application of chimeric antigen receptor
(CAR)-modified T cells in CD19-positive B cell
hematological malignancies has demonstrated the
potency of this approach for cancer immunotherapy
[6–9], and CAR T cells targeting a variety of different
hematologic and solid tumor antigens are under active
clinical development [10, 11]. Epidermal growth factor
receptor (EGFR), a receptor tyrosine kinase playing
key roles in the diverse processes that stimulate cell
proliferation, differentiation, migration, progression,
and survival, is overexpressed in 67–100% of biliary
cancers [12], making it a rational target for CART
immunotherapy. Hence, we moved forward the trial of
CART-EGFR immunotherapy (NCT01869166) in advanced
unresectable/metastatic CCA following the safety and feasi-
bility evaluation of CART-EGFR therapy in advanced non-
small cell lung cancer [13]. Meanwhile, we raised the
question of what the alternative target is if patients with
EGFR-positive CCA show resistance or relapse to the
CART-EGFR protocol. Besides tumor microenvironment
(TME), a very important factor in the regulation of tumor
angiogenesis, invasion, and metastasis, cancer stem cell
(CSC) is another key factor in CCA that is capable of pro-
moting tumor initiation, self-propagation and differenti-
ation, and resistance to chemotherapy and radiotherapy,
which could also be influenced by the interaction of cancer
cells, TME, and CSC [14, 15]. CD133 is a member of penta-
span transmembrane glycoproteins first identified in the
neuroepithelial stem cells in mice and later in normal
human somatic cells and various carcinomas including
CCA and serves as a specific molecular biomarker for CSC
[16], making it a reasonable target for immunotherapy.
In this manuscript, we report a case in which a patient
with advanced unresectable/metastatic CCA achieved an
8.5-month partial response (PR) from the initial CART-
EGFR treatment and obtained another 4.5-month PR when
switched to the CD133-specific CART immunotherapy
(registered as NCT02541370) after the resistance to CART-
EGFR therapy was confirmed. Based on this case, we define
this EGFR-specific and CD133-specific CART sequential
treatment as CART cocktail immunotherapy and recom-
mend a further investigation of its safety and feasibility.
Case presentation
Patient and medical history
A 52-year-old female with history of cholecystectomy
and partial resection of the hepatic left lobe in 2004 due
to symptomatic gallstone and multiple intrahepatic bile
duct cholelithiasis had intermittent fever and progressive
jaundice from the beginning of November 2014. Bile
duct obstruction and a suspected hepatic hilar malig-
nancy were detected through subsequent ultrasonog-
raphy, magnetic resonance cholangiopancreatography
(MRCP), magnetic resonance imaging (MRI), and posi-
tron emission tomography-computed tomography (PET-
CT) (Fig. 1a). Exploratory laparotomy was performed at
the end of November 2014 (Additional file 1: Figure S1)
and found severe intra-abdominal adhesion, a lump (1 ×
2 cm) with indurated texture in the proximal left hepatic
duct, and disseminated neoplastic lesions infiltrating the
hilum of the common hepatic duct, hepatoduodenum
ligament, the surrounding lymph nodes, hepatic artery,
portal vein, and celiac axis. These findings compelled
surgeons to give up radical resection. Purulent bile was
discharged from the common duct, and mucus plug pro-
truded from the wall of the bile duct. Partial neoplastic
lesions were removed from the enlarged lymph nodes,
the nub of the left hepatic duct, and the margin of the
common hepatic artery for pathological examination. T
duct drainage was installed for relief of biliary ob-
struction. Pathological reports revealed that the nature
of tumor was poorly differentiated adenocarcinoma
with differentiation markers of cholangiocyte; in
addition, moderate EGFR expression was detected in
>90% tumor cells. This patient was finally diagnosed
as advanced unresectable perihilar CCA. Five weeks
after palliative surgery, the patient received a 4-week
course of TOMO therapy on the hilar malignancy
(DT = 60 Gy/25 F), one cycle of systematic chemotherapy
with albumin-bound paclitaxel alone for her intolerable
gastrointestinal toxicities and the infusion of autologous
cytokine-induced killer cells. Because of the progressive
increase of CA199, PET-CT was re-examined immediately
after the completion of radiotherapy and showed a new
metastatic hypermetabolic lesion in the hepatic caudate
lobe and enlarged soft tissue and retroperitoneal lymph
node metastases with abnormal standardized uptake value
(SUV) between the liver and stomach when compared with
the PET-CT prior to radiotherapy (Fig. 1b). Four weeks
following radiotherapy, the patient was enrolled in the
CART-EGFR trial. Her performance status was 1 ac-
cording to the criteria of Eastern Cooperative Oncology
Group (ECOG). During the preparation of CART-EGFR
cells, she developed high fever, aggressive jaundice, and
obstruction of the biliary tract, accompanied by the
continuous elevation of CA199 (from 100.5 to 413.5 U/
ml), aggressive increase of total bilirubin, direct biliru-
bin, and other biliary obstruction-related enzymological
indexes and was treated with effective broad-spectrum
antibiotics and endoscopic biliary stent placement in
the hepatic bile ducts.
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Clinical design and protocol eligibility requirements
The trials (ClinicalTrials.gov identifier NCT01869166,
NCT02541370) were approved by the Institutional Re-
view Board at the Chinese PLA General Hospital. No
commercial sponsor was involved in the studies. The en-
rolled patients provided written informed consent ac-
cording to the Declaration of Helsinki.
Construction of the chimeric antigen receptor and
preparation of CART-EGFR and CART133 cells
The DNA sequence of single-chain fragment variable
(scFv) targeting EGFR antigen was derived from
JQ306330.1 (GenBank Number). Anti-EGFR scFv-
CD137-CD3zeta CAR was generated and cloned into
the pWPT lentiviral backbone, described in detail by
Feng et al. [13]. The construct was verified by DNA
sequencing. A pseudotyped, clinical-grade lentiviral
vector supernatant was produced by standard transi-
ent transfection as McGinley et al. described [17]. Ac-
cording to the manufacturer’s instructions of
Lipofectamine 3000 transfection reagent (Invitrogen,
USA), pWPT-anti-EGFR CAR plasmid, ps-PAX2 pack-
aging plasmid, and pMD2.G envelope plasmid were trans-
fected into 293 T cells. The lentiviral supernatants were
collected and stored at −80 °C. The GFP-CD137-CD3zeta
vector was constructed to verify the transduction effi-
ciency by means of FACSCalibur flow cytometry (BD Bio-
sciences). The DNA sequence of scFv targeting CD133
antigen was derived from HW350341.1 (GenBank Num-
ber), the generation, construction, and testing of CAR133
T cells followed the same procedure as CART-EGFR cells
(Additional file 2: Figure S2).
CART cells were manufactured from autologous
peripheral blood mononuclear cells (PBMCs) collected
in cell preparation tubes (BD Biosciences, San Jose,
CA) purified from 80 to 100 ml whole blood at the
Chinese PLA General Hospital Good Manufacturing
Practice Facility according to the current standard op-
erating procedures. PBMCs were stimulated with
50 ng/ml anti-CD3 MoAb (Takara, Japan) and 500 U/
ml recombinant human interleukin-2 (Peprotech,
USA) in GT-T551 medium (Takara). Lentiviral trans-
duction was performed in GT-T551 medium with
protamine sulfate (Sigma) for 24 h after 2 days of T
cell culture. Afterwards, the cells were further ex-
panded in culture bags (Takara) and harvested as
CART cells. Bacteria, fungi, and endotoxin were
tested before the infusion of CART cells.
Fig. 1 Changes of tumor lesions in sequential PET-CT examinations in the period of CART-EGFR cell infusion. a PET-CT examination illustrated hep-
atic hilar malignancy before surgery. b PET-CT examined after the completion of radiotherapy with illustration of a new metastatic hypermetabolic
lesion in the hepatic caudate lobe and enlarged soft tissue and retroperitoneal lymph node metastases. c PET-CT assessment 6 weeks after the in-
fusion of CART-EGFR cells showed a more than 80% shrinkage of metastatic lesions in the hepatic hilar region and caudate lobe. d Routine exam-
ination by PET-CT showed a persistent PR status 4 months after the CART-EGFR cell infusion. e PET-CT detected multiple new SUV abnormal
lesions in the omentum majus, peritoneum, and abdominal cavity 8.5 months after the first cycle of CART-EGFR cell infusion. f The examination of
PET-CT detected newly emerged metastases in the bottom of the pelvis, right liver lobe, and left supraclavicular lymph node as well as enlarge-
ment of previous tumor lesions in the abdomen 4 weeks after the combination of anti-PD-1 antibody and CART-EGFR
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Flow cytometry
The immunophenotype of CART cells was analyzed by
flow cytometry with fluorescently labeled antibodies spe-
cific for staining CD3, CD4, CD8, CD45RO, CD62L, and
CCR7. Isotype-matched monoclonal antibodies (BD Bio-
sciences) were used for control staining. CAR expression
was estimated based on GFP-CD137-CD3zeta-trans-
duced cells in the same batch for all patients by flow cy-
tometry. Data acquisition and analysis were performed
using a FACSCalibur flow cytometry (BD Biosciences).
In vitro cytotoxicity of CART-EGFR cells was tested by
co-culturing with EGFR-positive tumor cells at various
effector-to-target ratios in 96-well plates using a 4-h
CCK-8 Detection kit (DOJINDO, Japan).
Quantitative real-time PCR
Quantitative real-time PCR (Q-PCR) was employed
to assess the level of CAR fusion gene according to
a previously described protocol.13 A 153-bp (base
pair) fragment that contains portions of the CD8a
chain and adjacent 4-1BB chain (the forward primer
5′-GGTCCTTCTCCTGTCACTGGTT-3′ and reverse
primer 5′-TCTTCTTCTTCTGGAAATCGGCAG-3′)
was amplified by the ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems). Beta-actin
was used as an internal control. A 7-point standard
curve that consisted of 100 to 108 copies/μl plasmid
DNA containing the CAR gene was prepared.
Cytokine measurements
Serum IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-12/
IL23p40, IFN-γ, TNF-α, VEGF, and Granzyme B were
tested using a BD Biosciences microbead sandwich im-
munoassay according to the manufacturer’s instructions.
Results
Generation, phenotype, and transfection efficiency of EGFR-
specific and CD133-specific CART cells
According to the culturing system as reported previously
[13], CART-EGFR cells were generated from the mono-
nuclear cells of 80–100 ml of the patient’s peripheral
blood and released for the infusions. Of the infused cells
during the first cycle of CART-EGFR therapy, 99.14%
were CD3+ cells principally composed of the CD8+
subset (62.26%), and 23.61% were characterized with the
central memory phenotype (CD45RO+/CD62L+/CCR7
+). In addition, 8.99% of the infused cells were EGFR
positive. The phenotype and transfection efficiency of in-
fused CART-EGFR cells in each cycle are documented
in Table 1.
CART133 cells were generated and cultured according
to the same procedure of CART-EGFR cells. Of the in-
fused cells, 95.2% were CD3+ cells principally composed
of the CD8+ subset (71.9%), and 41.9% were CD45RO
+/CD62L+/CCR7+ subset. Besides, 6.4% of the infused
cells were CD133 positive. Details are documented in
Table 1.
The infusion of CART cells and clinical response
Because of the recently completed radiotherapy within
2 months and intolerance of chemotherapeutic agents, the
patient was administered with 4-day successive infusions
of 2.2 × 106/kg CART-EGFR cells in total without any
conditioning therapy, and achieved a PR in her first
assessment 6 weeks later, evaluated according to Response
Evaluation Criteria in Solid Tumors version 1.1 (RECIST
1.1) with both MRI and PET-CT, which illustrated a more
than 80% shrinkage of metastatic lesions in the hepatic
hilar region and caudate lobe and a remarkable decline of
the SUV (Fig. 1c), along with a rapid decrease of CA199
from 413.5 to 123.1 U/ml (Fig. 2). The CAR transgene
copy number in the patient’s peripheral blood reached a
peak of 5916 pg/dl at day 9 accompanied with release of
cytokines such as interleukin-6 (IL-6) and C reactive
protein (CRP) (Figs. 3 and 4). The second cycle of CART-
EGFR monotherapy was administered with a dose of
EGFR-CAR+ expressing T cells 2.1 × 106/kg and without
any pre-conditioning treatment because the CAR trans-
gene copy number in peripheral blood declined close to
the baseline level 2 months after the first infusion of CAR-
EGFR expressing genetically modified T cells. Routine
examinations of MRI and PET-CT showed a persistent PR
accompanied with a further reduction of CA199 to
61.2 U/ml (Figs. 1d and 2). Interestingly, the peak of CAR
transgene copy number after the second cycle infusion of
CART-EGFR cells did not reach a paralleled or higher
level as the first cycle of CART-EGFR therapy did (Fig. 3).
The PR status of the patient was maintained for
8.5 months until she developed frequent unmanageable
vomiting, upper abdominal dull pain, and gastric acid
reflux, which occurred in the middle of November 2015.
The subsequent electronic gastroscopy showed duodenal
bulb stricture, and PET-CT confirmed tumor progression
with illustration of multiple new SUV abnormal lesions in
the omentum majus, peritoneum, and abdominal cavity
(Fig. 1e).
Subsequently, the patient was treated with 1 cycle of
CART-EGFR therapy combined with 2 cycles of anti-
programmed cell death protein 1 (PD-1) monoclonal
antibody (Nivolumab, Bristol-Myers Squibb), which was
administered at a dose of 100 mg every 2 weeks. Like-
wise, the CAR transgene copy number monitored in
peripheral blood did not reach a similar peak level of the
first cycle infusion even combined with anti-PD-1 anti-
body (Fig. 3). Despite the serum CA199 declined transi-
ently from 326.3 to 210.8 U/ml (Fig. 2), the following
PET-CT detected newly emerged metastases in the
bottom of the pelvis, right liver lobe, and left
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supraclavicular lymph node as well as enlargement of
previous tumor lesions in the abdomen when compared
with the PET-CT before the combined immunotherapy
(Figs. 1f and 5a).
Because more than 90% tumor cells expressed
CD133 protein (Additional file 3: Figure S3), the pa-
tient was then enrolled into the CART133 trial and
received the infusion of 1.22 × 106/kg CD133-specific
CART cells without conditioning treatment. Because
of the occurrence of obstruction in the descending
duodenum and the resulting persistent severe biliary
tract infection as well as liver abscess, which may
interfere with the level of serum CA199 and was
treated with antibiotics, the scheduled imaging evalu-
ation was postponed until 2 months after the infusion
of CART133 cells, in which contrast-enhanced CT
showed remarkable shrinkage or even disappearance
of some metastases in the peritoneum and abdominal
cavity, leading to an evaluation of PR (Fig. 5b). The
CAR transgene copy number in peripheral blood (PB)
fluctuated from 377 to 919 pg/dl (Fig. 3). The patient
felt persistent dull pain in her upper abdomen
2.5 months later, and the subsequent CT scan de-
tected an approximate 40 × 70 mm new metastatic
lesion under the abdominal wall and suspected
metastases in the abdominal cavity accompanied by
CAR transgene copy number in PB decreasing close
to baseline level, drawing a conclusion of progressive
disease (PD) (Fig. 5c).
Toxicities
CART-EGFR Adverse events such as chills, fever, fatigue,
vomiting, and muscle soreness occurring during the infu-
sion of CART-EGFR cells were usually mild, tolerable, and
manageable by supporting care. However, the patient de-
veloped a 9-day lasting lower fever without chills, cough,
diarrhea, or any other infectious symptoms since the third
day following the CART cell infusion. Repeated laboratory
examination of PB showed normal white blood cell count,
neutrophil ratio, negative procalcitonin (PCT), and blood
cultures, which did not support the diagnosis of infection,
but meanwhile escalation of IL-6 and CRP (Fig. 4) and
acute increase of glutamic-pyruvic transaminase and
glutamic-oxalacetic transaminase (>6ULN). There were a
few scattered tiny rashes appeared in the left thigh 2 weeks
after the first cycle infusion of CART-EGFR cell, which
gradually worsened and became apparent and pruritic
with the presentation of multiple flaky or linear rashes
spreading from the left thigh to the calf and merging
























1 8.99 99.14 32.77 62.26 18.98 10.64 77.93 51.01 51.3 23.61 22.42
2 8.98 98.53 16.40 78.29 41.02 36.29 96.99 67.15 71.06 50.82 12.13
3 8.17 98.66 53.66 45.47 7.25 4.26 94.49 76.87 40.96 20.49 3.54
CD133 6.4 95.2 23.6 71.9 11.23 8.19 94.9 74.1 51.4 41.9 12.3
Fig. 2 Change of CA199 in the course of CART cocktail immunotherapy
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together, which was graded 2 according to the common
terminology criteria for adverse events 4.0 (CTCAE 4.0),
when the second cycle of CART immunotherapy was ful-
filled. The rashes were biopsied with illustration of lichen
striatus-like pathological changes such as the loss of par-
tial epidermis, vacuolar degeneration of basal cells, and in-
filtration of numerous T lymphocytes in the epidermis
and its appendages (Fig. 6a), and managed successfully
with tacrolimus ointment. No hypotension occurred
throughout the CART-EGFR treatment.
Combination of CART-EGFR and anti-PD-1 antibody
Except mild nausea, vomiting, chills, fever, and fatigue,
there were not any other acute adverse events occurred
in the course of the combination treatment. Though
dandruff appeared and worsened following the
combined immunotherapy, it was not in need of medical
interventions. Serum levels of cytokines such as tumor
necrosis factor-α (TNF-α), IL-6, and CRP elevated
slightly and did not induced any symptoms of cytokine
release.
CART133 During the infusion of successive dose-
escalating CART133 cells over 4 days, there were no any
other adverse events except infusion-related mild fever
and fatigue. However, on the second morning after the
completion of CART133 cell infusion, this patient devel-
oped intermittent upper abdominal dull pain, chills,
fever (39.1 °C), sporadic pinpoint hemorrhages, and con-
gestive rashes on her calves, which spread rapidly and
diffusedly to her neck, right upper arm, chest, left abdo-
men, and retropharyngeal mucosa accompanied by prur-
itus and diarrhea in that afternoon and deteriorated
Fig. 3 Transgene copy number of CAR DNA in PB throughout the treatment process
Fig. 4 The levels of IL-6 and CRP during and after the infusion of CART-EGFR and CART133 cells
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Fig. 5 Outcome of CART133 cell infusion. (a) With the guidance of PET, tumor lesions were labeled on the images presented by computed
tomography (CT) scans before the infusion of CART133 cells (red arrow). (b) CT images showed remarkable shrinkage or even disappearance of
some metastases in the peritoneum and abdominal cavity (red arrow) and an abscess in the right liver. (c) CT scan detected an approximate 40 ×
70 mm new metastatic lesion under the abdominal wall and suspected metastases in the abdominal cavity 4.5 months after the CART 133
immunotherapy (red arrow)
Fig. 6 Epidermal and endothelial damages caused by the infusion of CART cells. a Lichen striatus-like skin rashes appeared and worsened after
the CART-EGFR therapy with the illustration of pathological changes such as the loss of partial epidermis, vacuolar degeneration of basal cells,
and infiltration of numerous T lymphocytes in the epidermis and its appendages. b Diffused pinpoint hemorrhages and congestive rashes
occurred on her neck, right upper arm, chest, left abdomen, and retropharyngeal mucosa after the CART133 cell infusion
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furtherly in the following 10 days (Fig. 6b). The skin and
subcutaneous adverse events were graded 3 according to
CTCAE 4.0. Serial serum cytokine testing detected rapid
elevation of TNF-α, IL-6, and CRP (Fig. 4). Etanercept, a fu-
sion protein that acts as a TNF inhibitor, intravenous meth-
ylprednisolone, and gamma globulin were administered
immediately and successfully reversed the skin/mucosa
toxicities.
Discussion
The use of CAR-modified T cells to eradicate cancers has
been studied for more than 20 years until recently
CART19 produced promising results in CD19 expressing
hematological malignancies. However, how to translate
this exciting success of CART therapy to solid tumors
remained unclear, requiring a better understanding of
potential therapeutic barriers including factors that
regulate CART cell expansion, persistence and trafficking
in vivo, tumor microenvironment and its interaction with
tumor cells, and cancer stem cells as well as conditioning
therapies.
As Porter et al. pointed out that vigorous expansion and
persistence of CART cells in vivo is a critical determinant
of therapeutic efficacy [18], in this case, the CAR transgene
copy number in PB ascended to peak level immediately
after the beginning of CART-EGFR cell infusion, illustrating
that CART-EGFR cells underwent a robust expansion in
vivo, which is one of the premises of CART-EGFR cells
eliminating EGFR-expressing CCA cells. Besides, the
persistence of CART cells in vivo, in spite of a number of
possible interference factors such as CAR affinity for the
target, CAR immunogenicity, and host-derived factors, has
been suggested to be directly correlated with longer time to
progression [19]. This patient was treated with the second
cycle infusion of CART-EGFR cells as soon as the CAR
transgene copy number in PB dropped closely to the base-
line level 8 weeks after the first cycle infusion, enabling
CART cells effectively to persist in vivo for more than
24 weeks and the patient’s PR status to be sustained for
8.5 months, which may suggest that repeated infusions of
CARTcells could contribute to prolonging their persistence
in vivo and providing a longer progression free survival in
conditions where the targeted tumor responded to CART-
EGFR cells. Meanwhile, we also found that the CAR trans-
gene copy numbers of the subsequent cycles of CART cell
infusion could not reach a parallel or higher peak, even
combined with anti-PD-1 antibody, when compared with
that of the first cycle, indicating a weakening expansion of
CART cells in vivo and loss of CART cells. One potential
mechanism is that the murine scFv incorporated in the
CAR transgene may lead to the development of CD8+ Tcell
immunity [20].
The ultimate functional competence of CART cells in
solid tumors is determined by whether they can effectively
penetrate into the tumor microenvironment, a complex
and dense fibrotic matrix network orchestrated by both
malignant and non-malignant cells, in which the infil-
trated CART cells can be inhibited by immunosuppressive
cells and molecules such as Tregs, myeloid derived
suppressive cells (MDSCs), and programmed cell death
protein ligand 1 (PD-L1) [21, 22], resulting in rapid loss of
their cytolytic and cytokine secretion capacity and enter-
ing a state of hyporesponsiveness [23]. In addition, solid
tumors frequently demonstrate metabolic aberrations by
overconsuming key amino acids critical for T cell activity
and induce hypoxia and a resultant extracellular matrix
acidification due to insufficient vascular supply that is
hostile to T cell survival [24]. Thus, modulation of tumor
microenvironment is necessary to improve outcomes. In
this case, despite of the fact that the patient did not
receive any direct conditioning treatment with the pur-
pose of transforming the tumor microenvironment, she
was treated with 60 Gy radiotherapy prior to immunother-
apy with an approximately 1 month interval from the end
of radiotherapy to the beginning of CART cell infusion.
Although the radiotherapy itself failed to effectively eradi-
cate tumor cells, its direct and delayed effect may play
roles in destructing the tumor-supporting stroma, altering
the biology of the tumor microenvironment, promoting
the release of more tumor-associated antigens, and enhan-
cing immune recognition [25]. Moreover, radiotherapy
could make tumors more immunogenic and more suscep-
tible to an improved attack by the immune cells [26], and
even generate antitumor effects in those distant metastases
which were not locally irradiated (referred to as the absco-
pal effect) [27, 28]. Hereby, we put forward a hypothesis
that radiotherapy could be a reasonable and effective condi-
tioning therapy for improving the outcome of CART
therapy.
When the resistance to CART-EGFR therapy was con-
firmed, we once tried a combination immunotherapy by
anti-PD-1 antibody in conjunction with CART-EGFR cell
infusion on the basis of a preclinical study that blockade of
PD-1 immunosuppression could significantly enhance the
therapeutic efficacy of CART cell therapy against estab-
lished solid tumors [29]. Unfortunately, this treatment
ended in failure with PET-CT verifying the progression of
disease, although CA199 was transiently decreased. One
possible explanation is the unclear level of PD-L1 expres-
sion. Recently, PD-L1 expression is highlighted for its value
in predicting therapeutic effects of anti-PD-1 drugs. How-
ever, the tumor lesion in this case was difficult for biopsy
for its anatomic location, resulting that the level of PD-L1
protein expression on tumor cells could not be accurately
detected before the initiation of anti-PD-1 therapy, which
exist a possibility that PD-L1 expression in tumor milieu
might be low level or even negative and therefore lead to
the failure of anti-PD-1 treatment. Meanwhile, there were
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many other parallel checkpoint pathways that could poten-
tially support resistance to anti-PD-1 therapy [30]. Under
this situation, selecting a rational target was crucial for the
next-step of the patients’ treatment. Recently, the CSCs in
CCA have attracted great attention for their highly carcino-
genic properties and key roles in mediating self-renewal,
tumor re-growth, and therapeutic resistance, consequently,
therapy which targeted surface molecular markers and sig-
naling pathways specific to CSC would be a possible potent
option for CCA [15, 31]. Among the molecules used indi-
vidually or in combination to identify cholangiocarcinoma
stem cells, CD133 is one of the most important stem cell
markers that are associated with higher invasiveness and
poorer prognosis [32]. Shien and colleagues also reported
that CD133-positive tumor cells showed greater resistance
to post-operative treatment than CD133 negative cells, and
increased CD133 expression was observed in residual
cancer cells after adjuvant therapy [33]. Base on the above,
we finally selected CD133 as the target antigen for CART
immunotherapy, which in turn produced another partial
response, and further demonstrated that CART cocktail
immunotherapy may be feasible and rational.
Another crucial issue be of great concern was the toxicity,
which could be induced by CART cells on the target anti-
gens expressed on tumor and/or synchronously on normal
tissues, termed as on-target off-tumor effect. Damage to
normal tissues may even occur by unexpected cross-
reaction with a protein that is not expressed on tumor cells
[34]. Since the initiation of CART-EGFR cell infusion, this
patient experienced not only infusion-related fever, chills,
and fatigue, but also sustained pyrexia, acute elevation of
serum transaminases, and delayed onset of skin rashes,
accompanied by robust elevation of CAR transgene copy
number, IL-6, and CRP, although the levels of which did
not meet the criteria of diagnosing cytokine-release syn-
drome [35, 36]. The massive cytokines that might be
directly produced by the infused CART cells reflected a
strong immune response that could generate both antitu-
mor effects on tumor cells and side effects on normal
tissues. In addition, the on-target off-tumor effect caused
by CART-EGFR cells was probably the reason for the trig-
gering of dermal toxicities due to the distribution of EGFR
on the epidermis [37]. However, all of these adverse events
were mild, reversible, and managed with supportive care
and topical corticosteroid. The addition of anti-PD-1 anti-
body did not apparently aggravate the toxicities of CART-
EGFR immunotherapy in this case. Nonetheless, in the
subsequent treatment of CART133 cell infusion, this
patient suffered severe dermatologic, oral mucousal, and
gastrointestinal toxicities such as congestive rash and
hemorrhage. Although these toxicities were managed
successfully by emergent medical interventions including
intravenous methylprednisolone and anti-TNF inhibitor,
the inherent mechanism may largely be due to the on-
target off-tumor effect of CART133 cells which targeted
on the CD133 antigen expressed on normal epithelium
and vascular endothelium. Meanwhile, it was unclear
whether the anti-PD-1 antibody and residual CART-EGFR
cells in vivo could play a role in deteriorating the toxicities
of CART133 immunotherapy.
Conclusions
In spite of the mounting achievements in the treatment of
hematological malignancies to date, unfortunately, CART
immunotherapy is still fraught with many particular obsta-
cles in solid tumors [38], requiring appropriate solutions in
order to advance CART cell therapy. The success of this
case suggests that CART cocktail immunotherapy may be
feasible for the treatment of solid malignancies. However,
the known and unknown toxicities, especially the epider-
mal/endothelial damages, should be further investigated for
fully evaluating its safety.
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Additional file 1: Figure S1. Diagrammatic sketch of the treatments.
(TIF 248 kb)
Additional file 2: Figure S2. Characteristics of CART-133 cells. (A)
Schematic representation of anti-CD133 CAR, not to scale. (B) Specific
cytotoxicity of CART-133 cells to the CD133-expressing tumor cells.
Results of a 4-hour CCK8 analysis at effector/tumor cell (E:T) ratio of
1:1 and 5:1. The effector cells were CART-133, mock, and non-viral transduction
T (NT) cells. The target cells were LOVO (CD133−) human colon carcinoma cell
line, HepG2 (CD133−) human hepatocellular carcinoma cell line, SW620
(CD133+) human colon carcinoma cell line, and SW1990 (CD133+) human
pancreatic cancer cell line. Results are representative as means ± SD (*P< 0.05,
two-way ANOVA test, GraphPad Prism 6.0). (TIF 340 kb)
Additional file 3: Figure S3. CD133 expression tested with
immumohistochemical staining. (TIF 1.37 mb)
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